Comparing responsiveness of the EQ-5D-5L, EQ-5D-3L and EQ VAS in stroke patients

Abstract

AimsTo date, evidence to support the construct validity of the EQ-5D-5L has primarily focused on cross-sectional data. The aims of this study were to examine the responsiveness of EQ-5D-5L in patients with stroke and to compare it with responsiveness of EQ-5D-3L and visual analogue scale (EQ VAS).MethodsWe performed an observational longitudinal cohort study of patients with stroke. At 1 week and 4 months post-stroke, patients were assessed with modified Rankin Scale (mRS) and Barthel Index (BI) and were administered the EQ-5D-5L and EQ-5D-3L, including the EQ VAS. The EQ-5D-5L index scores were derived using the crosswalk methodology developed by the EuroQol Group. We classified patients according to two external criteria, based on mRS or BI, into 3 categories: ‘improvement,’ ‘stable’ or ‘deterioration’. We assessed the responsiveness of each measure in each patient subgroup using: effect size (ES), standardized response mean (SRM), F-statistic, relative efficiency and area under the receiver operating characteristic curve.ResultsA total of 112 patients (52 % females; mean age 70.6 years; 93 % ischemic stroke) completed all the instruments at both occasions. In subjects with clinical improvement, EQ-5D-5L was consistently responsive, showing moderate ES (0.51–0.71) and moderate to large SRM (0.69–0.86). In general, EQ-5D-3L index appeared to be more responsive (ES 0.63–0.82; SRM 0.77–1.06) and EQ VAS less responsive (ES 0.51–0.65; SRM 0.59–0.69) than EQ-5D-5L index.ConclusionsThe EQ-5D-5L index, based on the crosswalk value set, seems to be appropriately responsive in patients with stroke, 4 months after disease onset. As far as EQ-5D-5L index is scored according to crosswalk approach, the EQ-5D-3L index appears to be more responsive in stroke population.

Psychometric properties of the EQ-5D-5L in Thai patients with chronic diseases

“…For the worsened group, the SES of the EQ-5D-5L index were considered small (-0.29) but that of the EQ-VAS considered large (-0.82). Compared to a study in stroke patients [16], they found that SES of EQ-5D-5L index and EQ-VAS were medium (0.51-0.71) in patients with clinical improvement and small [-0.13 to (-0.45)] for the deteriorated group. This conflicts with our results that the EQ-5D-5L index was less responsive in the improved group, but the EQ-VAS was more responsive in the worsened group.…”

“…Several studies have shown that the EQ-5D-5L has good psychometric properties [12][13][14][15][16][17][18][19]. These studies were conducted in both general populations [12,13] and patient groups including cancer [14], hepatitis [15], stroke [16,17], Parkinson's disease [18], and HIV/AIDS [19]. Only one study was conducted in general population with chronic diseases [20].…”

Health utility reporting in chronic rhinosinusitis patients

“…We are limited by the lack of UK studies that use the newest version of the EQ-5D (5 level version as used in this study) when putting this figure into context. Data from the USA shows patients with COPD to have an index score of 0.79 21 and European data showed a score of 0.69 in patients 4 months after a stroke 22 Hence, our study would suggest that CRS does impact on quality of life and perhaps surprisingly to similar scale as that seen in other chronic disease states.…”

EQ-5D in Central and Eastern Europe: 2000–2015

“…Eleven studies (8%) employed the EQ-5D-5L [46,65,88,97,77,81,82,130,164,160,165]. No articles reported results on the youth version of the questionnaire (EQ-5D-Y), possibly because the validation process of the CEE national language versions was only completed in May 2015.…”

“…These were conducted in Bulgaria (n=1), Hungary (n=4), Poland (n=6) and Slovenia (n=3). Among these, we found representative population norms from Hungary, Poland and Slovenia [11,136,149,115,164,180]. Further, local population norm is available for the city of Burgas in Bulgaria [59].…”